The U.S. pharmaceutical CDMO for formulations market size was estimated at USD 11.00 billion in 2025 and is projected to be worth around USD 22.05 billion by 2035, is expanding at a CAGR of 7.20% from 2026 to 2035. Due to increasing outsourcing by pharma and bio tech companies seeking cost efficiency, faster development, and regulatory expertise, rising demand for biologics, specialty drug and complex formations, along with generic drug expansion and patient expires, is for the driving market growth and collaborations.

U.S. Pharmaceutical CDMO for Formulations Market Statical Scope

It is the shift towards integrated, end-to-end services covering formulation development, testing and commercial manufacturing, companies are also investing in advanced facilities to strength domestic supply chains and ensure scalability, especially for biologics , injectables, and high potency drugs.

Technological advancement or enhancing efficiency and product quality, with adoption of AI- driven in formulation design, continuous manufacturing, automation, an advanced drug delivery systems like nano formulation, these innovations are improving speed, precision, and sustainability in pharmaceutical production.

U.S. Pharmaceutical CDMO For Formulation Market, By Dosage Form Share, 2025 (%)

• Oral Solids - The oral solids segment dominated the market with a share of 34% in 2025, due to easy administration, high patient compliance, cost-effective large-scale production, and strong demand for tablets and capsules in chronic therapies.
• Oral Liquids - The oral liquids are rapidly growing with a market share of 11%, because they are less stable, need preservatives, have sorters shelf life, and are mainly preferred for geriatric and patient with swallowing difficulties.
• Injectables - The injectables segment held a 28% market share in 2025 and is expected to grow at a steady rate, due to high demand of biologics, vaccines and targeted therapies that require rapid action, precise dosing, and better bioavailability.

U.S. Pharmaceutical CDMO For Formulation Market, By Application Share, 2025 (%)

• Oncology - The oncology segment dominated the market with a share of 31% in 2025, due to rising cancer prevalence, strong demand for advanced target and biologic therapies, and continuous innovation in complex and personalised treatment formulations.
• Cardiology - The cardiology segment held a 17% market share in 2025 and is expected to grow at a steady rate, due to high prevalence of cardiovascular diseases, growing ageing population, and continuous demand for long term oral injectable heart therapies.
• Central Nervous System - The central nervous system are rapidly growing with a market share of 19%, due to rising neurological disorders like Alzheimer's, and depression, driving demand for advanced, controlled release and specialty central nervous system drug formulations.

U.S. Pharmaceutical CDMO For Formulation Market, By End-User Share, 2025 (%)

• Pharmaceutical Companies - The pharmaceutical companies segment dominated the market with a share of 56% in 2025, because they extensively outsource development and manufacturing to reduce costs, speed up drug launches, and focus on core research and marketing activities.
• Biopharmaceutical Companies - The biopharmaceutical companies segment held a 34% market share in 2025 and is expected to grow at a steady rate, because the increasingly outsource complex biologics and specialty drug formulation to excess advanced technologies, reduce costs, an accelerated development timelines.
• Others - The others are rapidly growing with a market share of 10%, because it includes players like academic institute in small firms with limited outsourcing needs, lower production volumes and less dependence on partnerships.

Top Companies in the U.S. Pharmaceutical CDMO for Formulations Market

• Lonza
• Thermo Fisher Scientific, Inc.
• Recipharm AB
• Laboratory Corporation of America Holdings (LabCorp)
• Catalent, Inc.
• WuXi AppTec, Inc.
• Piramal Pharma Solutions
• Siegfried Holding AG
• CordenPharma International
• Cambrex Corporation
• Bushu Pharmaceuticals Ltd.
• Nipro Corporation
• EuroAPI
• Hovione
• Curia

Segments Covered in the Report

By Dosage Form

• Oral Solids
• Oral Liquids
• Injectables
• Topicals
• Inhalation Products
• Transdermal And Patches
• Others

By Therapeutic Area

• Oncology
• Cardiology
• Central Nervous System
• Gastroenterology
• Infectious Diseases
• Endocrinology (Diabetes, Hormonal Therapy)

By End User

• Pharmaceutical Companies
• Biopharmaceutical Companies
• Others